bluebird bio Announces FDA Approval of ZYNTEGLO, the First Gene Therapy for People with…
bluebird bio, Inc. announced the U.S. Food and Drug Administration (FDA) has approved ZYNTEGLO (betibeglogene autotemcel), also known as beti-cel, a one-time gene therapy…
Read More...
Read More...
